A new SARS-CoV-2 variant B.1.1.529 was named by the WHO as Omicron and classified as a Variant of Concern (VOC) on 26 November 2021. Because this variant has more than 50 mutations, including 30 mutations on the spike, it has generated a lot of concerns on the potential impacts of the VOC on COVID-19. Here through ELISA assays using the recombinant RBD proteins with sequences the same to that of SARS-CoV-2 WIV04 (lineage B.1), the Delta variant and the Omicron variant as the coating antigens, the binding capabilities between the RBDs and the antibodies in COVID-19 convalescent sera and vaccine sera after two doses of the inactivated vaccine produced by Sinopharm WIBP are compared with each other. The results showed that the Omicron variant may evade antibodies induced by the ancestral strain and by the inactivated vaccine, with significant reduction in the binding capability of its RBD much greater than that of the Delta variant.
【저자키워드】 SARS-CoV-2, antibody, variants of concern, omicron, Receptor-binding domain, Inactivated vaccine, 【초록키워드】 COVID-19, Vaccine, Mutation, VoC, mutations, variant, omicron, delta variant, Inactivated vaccine, RBD, sera, Impact, antigens, Omicron variant, B.1.1.529, concern, convalescent sera, ELISA assay, binding, Sinopharm, dose, RBDs, sequences, sequence, lineage B.1, ELISA assays, recombinant RBD proteins, recombinant RBD protein, new SARS-CoV-2, greater, produced, the RBD, evade, the WHO, reduction in, the antibody, 【제목키워드】 COVID-19, Inactivated vaccine, RBD, B.1.1.529, Decline,